Glycolithocholic Acid
(Synonyms: 甘氨石胆酸,Lithocholylglycine) 目录号 : GC43778
Glycolithocholic Acid是次级胆汁酸与甘氨酸的结合物，为体内内源性代谢产物。
Cas No.:474-74-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Glycolithocholic Acid, a conjugate of secondary bile acids and glycine, is an endogenous metabolic product within the body[1]. Changes in the concentration of Glycolithocholic Acid in serum or tissues can assist in the diagnosis of non-alcoholic steatohepatitis (NASH), ulcerative colitis (UC), and primary sclerosing cholangitis (PSC)[2].
In vivo, Glycolithocholic Acid treatment via intravenous injection (16μmol/100g body weight; once a week for 8 weeks) significantly increased the frequency of T regulatory cells and promoted osteogenic differentiation of mesenchymal stem cells, alleviating osteoporosis in rats following ovariectomy[3].
References:
[1] Cowen A R, Hofmann A F, Cass O W. Metabolism of Lithocholate in Healthy Man: I. Biotransformation and biliary excretion of intravenously administered lithocholate, lithocholylglycine, and their sulfates[J]. Gastroenterology, 1975, 69(1): 59-66.
[2] Raufman J P, Zimniak P, Bartoszko-Malik A. Lithocholyltaurine interacts with cholinergic receptors on dispersed chief cells from guinea pig stomach[J]. American Journal of Physiology-Gastrointestinal and Liver Physiology, 1998, 274(6): G997-G1004.
[3] Cai X, Li Z, Yao Y, et al. Glycolithocholic acid increases the frequency of circulating Tregs through constitutive androstane receptor to alleviate postmenopausal osteoporosis[J]. Biochemical Pharmacology, 2024, 219: 115951.
Glycolithocholic Acid是次级胆汁酸与甘氨酸的结合物，为体内内源性代谢产物[1]。Glycolithocholic Acid在血清或组织中浓度的变化可用于辅助诊断非酒精性脂肪性肝炎（NASH）、溃疡性结肠炎（UC）和原发性硬化性胆管炎（PSC）[2]。
在体内，大鼠经静脉注射Glycolithocholic Acid（16μmol/100g，每周一次，持续8周）后，可显著增加调节性T细胞频率并促进间充质干细胞成骨分化，从而缓解卵巢切除术后骨质疏松症[3]。
| Animal experiment [1]: | |
Animal models | Sprague-Dawley rats |
Preparation Method | Specific pathogen-free female 6-month-old Sprague-Dawley rats were housed in a specific pathogen-free animal center. The rats were allowed to adapt to the housing environment for the first 3 days and then underwent bilateral ovariectomy on the 4th day. The surgical procedure was as follows: anesthetize, fix, and disinfect the rats; make an incision in the abdomen; remove the ovaries; ligate; and suture to establish the ovariectomy (OVX) rat model. After the surgery, the rats were given intramuscular injections of penicillin sodium (320μL/200g body weight) to reduce infection. The sham surgery group (sham) rats had an incision and sutures without removing the ovaries. On the 30th day, all rats were intravenously injected with 16μmol/100g of Glycolithocholic Acid. The injections were started on day 30 following OVX model establishment, once a week, for a total of eight injections. The rats in the control group were injected with normal saline. Afterward, the rats were sacrificed, and tissue samples were collected for analysis. |
Dosage form | 16μmol/100g body weight; once a week for 8 weeks; i.v. |
Applications | Glycolithocholic Acid treatment significantly increased the frequency of T regulatory cells and promoted osteogenic differentiation of mesenchymal stem cells, alleviating osteoporosis in rats. |
References: | |
| Cas No. | 474-74-8 | SDF | |
| 别名 | 甘氨石胆酸,Lithocholylglycine | ||
| 化学名 | N-[(3α,5β)-3-hydroxy-24-oxocholan-24-yl]-glycine | ||
| Canonical SMILES | C[C@H](CCC(NCC(O)=O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@@]21C | ||
| 分子式 | C26H43NO4 | 分子量 | 433.6 |
| 溶解度 | 20mg/mL in ethanol & DMSO, 30mg/mL in DMF | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3063 mL | 11.5314 mL | 23.0627 mL |
| 5 mM | 0.4613 mL | 2.3063 mL | 4.6125 mL |
| 10 mM | 0.2306 mL | 1.1531 mL | 2.3063 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet